Neuroprotective effect of agmatine in mouse spinal cord injury model:  Modulation by imidazoline receptors

Madhura DIxit; Manoj Upadhya; Brijesh Taksande; Prachi Raut; Milind Umekar; Nandkishor Kotagale

doi:10.4103/jnsbm.JNSBM_239_17

Neuroprotective effect of agmatine in mouse spinal cord injury model: Modulation by imidazoline receptors

Madhura DIxit, Manoj Upadhya, Brijesh Taksande, Prachi Raut, Milind Umekar, Nandkishor Kotagale^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: The involvement of imidazoline receptors in the effect of agmatine was studied in locomotor recovery following experimental SCI (ESCI) in mice. Methods: ESCI was induced in mice using compression method. Locomotor function score (0-10) was measured on day 14 following ESCI. Results: Agmatine (2.5, 5, and 10 mg/kg) treatment through intraperitoneal route for 14 days following ESCI, dose-dependently improved the motor function score. Clonidine (0.1 mg/kg; imidazoline I1 receptor agonist) or moxonidine (0.5 mg/kg; I2 receptor agonist) treatment 15 min before agmatine (2.5 mg/kg) daily for 14 days, following ESCI, significantly potentiated the effect of per se agmatine. On the other hand, 15 min before treatment of efaroxan (1 mg/kg; imidazoline I1 receptor antagonist) or idazoxan (3 mg/kg; imidazoline I2 receptor antagonist) significantly blocked the motor function score of agmatine (10 mg/kg). Conclusion: These data suggest that imidazoline receptors may modulate the locomotor recovery following ESCI in agmatine treated mice, perhaps through I1/I2 receptors.

Original language	English
Pages (from-to)	115-120
Number of pages	6
Journal	Journal of Natural Science, Biology and Medicine
Volume	9
Issue number	2
DOIs	https://doi.org/10.4103/jnsbm.JNSBM_239_17
Publication status	Published - 1 Jul 2018

Bibliographical note

This is an open access journal, and articles are distributed under the terms of the
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which
allows others to remix, tweak, and build upon the work non-commercially, as long
as appropriate credit is given and the new creations are licensed under the identical
terms.

Keywords

Agmatine
imidazoline receptors
locomotor recovery
motor function score
spinal cord injury

Access to Document

10.4103/jnsbm.JNSBM_239_17Licence: CC BY-NC-SA 3.0

Neuroprotective effect of agmatine in mouse spinal cord injury modelFinal published version, 788 KBLicence: CC BY-NC-SA 3.0

Cite this

@article{bfb052163ac84b25a78954a42f558e1f,

title = "Neuroprotective effect of agmatine in mouse spinal cord injury model: Modulation by imidazoline receptors",

abstract = "Objective: The involvement of imidazoline receptors in the effect of agmatine was studied in locomotor recovery following experimental SCI (ESCI) in mice. Methods: ESCI was induced in mice using compression method. Locomotor function score (0-10) was measured on day 14 following ESCI. Results: Agmatine (2.5, 5, and 10 mg/kg) treatment through intraperitoneal route for 14 days following ESCI, dose-dependently improved the motor function score. Clonidine (0.1 mg/kg; imidazoline I1 receptor agonist) or moxonidine (0.5 mg/kg; I2 receptor agonist) treatment 15 min before agmatine (2.5 mg/kg) daily for 14 days, following ESCI, significantly potentiated the effect of per se agmatine. On the other hand, 15 min before treatment of efaroxan (1 mg/kg; imidazoline I1 receptor antagonist) or idazoxan (3 mg/kg; imidazoline I2 receptor antagonist) significantly blocked the motor function score of agmatine (10 mg/kg). Conclusion: These data suggest that imidazoline receptors may modulate the locomotor recovery following ESCI in agmatine treated mice, perhaps through I1/I2 receptors.",

keywords = "Agmatine, imidazoline receptors, locomotor recovery, motor function score, spinal cord injury",

author = "Madhura DIxit and Manoj Upadhya and Brijesh Taksande and Prachi Raut and Milind Umekar and Nandkishor Kotagale",

note = "This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.",

year = "2018",

month = jul,

day = "1",

doi = "10.4103/jnsbm.JNSBM_239_17",

language = "English",

volume = "9",

pages = "115--120",

journal = "Journal of Natural Science, Biology and Medicine",

issn = "0976-9668",

publisher = "Wolters Kluwer Medknow Publications",

number = "2",

}

TY - JOUR

T1 - Neuroprotective effect of agmatine in mouse spinal cord injury model

T2 - Modulation by imidazoline receptors

AU - DIxit, Madhura

AU - Upadhya, Manoj

AU - Taksande, Brijesh

AU - Raut, Prachi

AU - Umekar, Milind

AU - Kotagale, Nandkishor

N1 - This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objective: The involvement of imidazoline receptors in the effect of agmatine was studied in locomotor recovery following experimental SCI (ESCI) in mice. Methods: ESCI was induced in mice using compression method. Locomotor function score (0-10) was measured on day 14 following ESCI. Results: Agmatine (2.5, 5, and 10 mg/kg) treatment through intraperitoneal route for 14 days following ESCI, dose-dependently improved the motor function score. Clonidine (0.1 mg/kg; imidazoline I1 receptor agonist) or moxonidine (0.5 mg/kg; I2 receptor agonist) treatment 15 min before agmatine (2.5 mg/kg) daily for 14 days, following ESCI, significantly potentiated the effect of per se agmatine. On the other hand, 15 min before treatment of efaroxan (1 mg/kg; imidazoline I1 receptor antagonist) or idazoxan (3 mg/kg; imidazoline I2 receptor antagonist) significantly blocked the motor function score of agmatine (10 mg/kg). Conclusion: These data suggest that imidazoline receptors may modulate the locomotor recovery following ESCI in agmatine treated mice, perhaps through I1/I2 receptors.

AB - Objective: The involvement of imidazoline receptors in the effect of agmatine was studied in locomotor recovery following experimental SCI (ESCI) in mice. Methods: ESCI was induced in mice using compression method. Locomotor function score (0-10) was measured on day 14 following ESCI. Results: Agmatine (2.5, 5, and 10 mg/kg) treatment through intraperitoneal route for 14 days following ESCI, dose-dependently improved the motor function score. Clonidine (0.1 mg/kg; imidazoline I1 receptor agonist) or moxonidine (0.5 mg/kg; I2 receptor agonist) treatment 15 min before agmatine (2.5 mg/kg) daily for 14 days, following ESCI, significantly potentiated the effect of per se agmatine. On the other hand, 15 min before treatment of efaroxan (1 mg/kg; imidazoline I1 receptor antagonist) or idazoxan (3 mg/kg; imidazoline I2 receptor antagonist) significantly blocked the motor function score of agmatine (10 mg/kg). Conclusion: These data suggest that imidazoline receptors may modulate the locomotor recovery following ESCI in agmatine treated mice, perhaps through I1/I2 receptors.

KW - Agmatine

KW - imidazoline receptors

KW - locomotor recovery

KW - motor function score

KW - spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=85049406089&partnerID=8YFLogxK

UR - http://www.jnsbm.org/downloadpdf.asp?issn=0976-9668;year=2018;volume=9;issue=2;spage=115;epage=120;aulast=Dixit;type=2

U2 - 10.4103/jnsbm.JNSBM_239_17

DO - 10.4103/jnsbm.JNSBM_239_17

M3 - Article

AN - SCOPUS:85049406089

SN - 0976-9668

VL - 9

SP - 115

EP - 120

JO - Journal of Natural Science, Biology and Medicine

JF - Journal of Natural Science, Biology and Medicine

IS - 2

ER -